Key Metrics of Niagen Bioscience Inc.
Revenue$83.6M▲ 16.0% YoYFY 2023
Operating income−$5.6M▲ 69.9% YoY
Net profit−$4.9M▲ 70.1% YoY
Shareholders' equity$28.5M
Market cap$193MNAGE · $2.44
Competitors10identified
About Niagen Bioscience Inc.
Sectors
Company details
- Listed
- Nasdaq: NAGE
Operational Areas of Niagen Bioscience Inc.
Pharmaceuticals & Healthcare›Formulations & Contract Manufacturing
Company summary
Legal nameNiagen Bioscience Inc.
TickerNAGE
ExchangeNasdaq
CountryUnited States
SEC CIK0001386570
Listed since—
Industry Medicinal Chemicals and Botanical Products
SectorPharmaceuticals & Healthcare · Formulations & Contract Manufacturing
Website—
US market & SEC filings
NAGE · Nasdaq · SEC CIK 0001386570
Last price · 28 Oct 2026
$2.44
+0.41%
Market cap$193M
P/E—On FY 2023 diluted EPS
Volume405,835
SectorHealth Care Medicinal Chemicals and Botanical Products
Country · IPOUnited States
NAGE share price
Premium
Annual results (SEC EDGAR)
Revenue, operating income, net income, EPS, cash flow, assets, liabilities, equity and debt for every year filed with the SEC are part of the premium plan.
Sign in to continue See plans & pricingVendor checks & payment capacity
Sign in with access to company financials to review vendor evidence.
Registered office and contact
Registered office—
GSTIN—
Email—
Website—
Members / shareholders—
Directors and key people
Directors are read from the MGT-7 annual return and AOC-4 signatories.
Competitors of Niagen Bioscience Inc.
Competitors10identified
Countries1most in United States
Top competitors by location
| Company | Description | Domain | Founded | Location |
|---|---|---|---|---|
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | lilly.com | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | jjmt.com.tw | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | pg.com | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | merck.com | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | amgen.com | 1983 | United States | |
| Part of Gilead Sciences. | gilead.com | 1992 | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | abbott.com | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | pfizer.com | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | bms.com | — | United States | |
| Formulations & Contract Manufacturing · Pharmaceuticals & Healthcare | marriott.com.cn | — | United States |
Charges (secured borrowings)
0 registered charges. Lenders, amounts and dates are part of the premium plan.
Statutory auditors
Auditors are read from the AOC-4 auditor's report section.
Business activities and related parties
Principal business activities and related-party transactions are read from MGT-7 and AOC-4 filings.
Filings
No filings on record yet.